Investigating the potential neurorestorative effects of a clinical Sigma-1 receptor agonist in a mouse model of Parkinson’s disease
Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer’s Disease Patients.
Anavex Life Sciences and Ariana Pharma Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
Anavex Life Sciences’ Drug Shows Efficacy to Support Potential Disease Modification in Parkinson’s Disease
